Ontology highlight
ABSTRACT:
SUBMITTER: Fruhwurth S
PROVIDER: S-EPMC6487575 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Fruhwürth Stefanie S Krieger Sigurd S Winter Katharina K Rosner Margit M Mikula Mario M Weichhart Thomas T Bittman Robert R Hengstschläger Markus M Stangl Herbert H
Biochimica et biophysica acta 20140405 7
The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis. Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia. Scavenger receptor, class B, type I (SR-BI) is the major HDL receptor and consequently regulating HDL-cholesterol levels and the athero-protective effects of HDL. By using ...[more]